Needham & Company LLC Reaffirms “Buy” Rating for Collegium Pharmaceutical, Inc. (COLL)
Collegium Pharmaceutical, Inc. (NASDAQ:COLL)‘s stock had its “buy” rating restated by equities research analysts at Needham & Company LLC in a research note issued to investors on Friday. They currently have a $25.00 price objective on the specialty pharmaceutical company’s stock. Needham & Company LLC’s target price would indicate a potential upside of 119.68% from the company’s current price.
Several other equities analysts also recently weighed in on the company. Jefferies Group LLC reissued a “buy” rating and set a $15.00 price target on shares of Collegium Pharmaceutical in a research report on Friday. HC Wainwright began coverage on Collegium Pharmaceutical in a research report on Monday, September 11th. They set a “buy” rating and a $21.00 price target for the company. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, September 8th. Zacks Investment Research raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. Finally, BidaskClub downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. Collegium Pharmaceutical presently has an average rating of “Hold” and a consensus price target of $20.00.
Shares of Collegium Pharmaceutical (COLL) opened at 11.38 on Friday. Collegium Pharmaceutical has a one year low of $9.27 and a one year high of $18.67. The stock’s market capitalization is $336.46 million. The firm has a 50-day moving average price of $10.46 and a 200 day moving average price of $10.46.
Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.09. The company had revenue of $3.56 million during the quarter, compared to the consensus estimate of $4.07 million. Collegium Pharmaceutical had a negative return on equity of 93.73% and a negative net margin of 1,319.39%. On average, equities analysts expect that Collegium Pharmaceutical will post ($3.00) EPS for the current fiscal year.
A number of hedge funds have recently bought and sold shares of COLL. American International Group Inc. grew its position in Collegium Pharmaceutical by 27.8% during the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock valued at $100,000 after acquiring an additional 2,163 shares during the period. Nationwide Fund Advisors grew its position in Collegium Pharmaceutical by 16.4% during the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock valued at $101,000 after acquiring an additional 1,422 shares during the period. Voya Investment Management LLC purchased a new stake in Collegium Pharmaceutical during the second quarter valued at about $125,000. Credit Suisse AG grew its position in Collegium Pharmaceutical by 9.4% during the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock valued at $137,000 after acquiring an additional 1,173 shares during the period. Finally, UBS Group AG grew its position in Collegium Pharmaceutical by 283.2% during the first quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock valued at $139,000 after acquiring an additional 10,174 shares during the period. 83.04% of the stock is owned by hedge funds and other institutional investors.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.